<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773575</url>
  </required_header>
  <id_info>
    <org_study_id>18P.577</org_study_id>
    <nct_id>NCT03773575</nct_id>
  </id_info>
  <brief_title>Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications</brief_title>
  <acronym>PREVENA-AMP</acronym>
  <official_title>Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acelity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multi-center, two-arm, unblinded, and randomized controlled
      trial with a goal of evaluating the impact of a closed incision negative pressure dressing
      (PREVENA) on incidence of post-operative wound complications and medical costs in patients
      undergoing lower extremity amputation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, two-arm, unblinded, randomized controlled trial to
      evaluate the impact of a closed incision negative pressure dressing (PREVENA™ PEEL &amp; PLACE™
      Dressing Kit) on incidence of post-operative wound complications in patients undergoing
      above-the-knee (AKA) or below-the-knee (BKA) amputation. Up to 440 subjects at approximately
      five (5) participating sites will be randomized to receive either the Prevena dressing or a
      standard care dressing. The incision will be assessed for complications at post-op day 5 or
      day 6 and at approximately 30 days after discharge. The primary outcome of this study is
      reported wound complications, including dehiscence (opening of the incision), seroma, lymph
      leak, infection (deep or superficial), hematoma (blood clots), ischemia (decreased blood
      supply), and necrosis (tissue death) A major complication is defined as any wound
      complication requiring intravenous or oral antibiotics, reoperation and/or hospital
      readmission. All data (demographics, medical history, and clinical outcomes) will be
      collected via medical record review
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall rate of wound complications</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Presence of any of the following post-procedure:
Dehiscence (skin or fascia)
Seroma
Lymph leak
Infection (superficial or deep, using CDC Surgical Site Infection criteria)
Hematoma
Ischemia
Necrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay (LOS)</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>index LOS is defined as days from operation to discharge; 30d LOS is defined as the index LOS plus all readmission days within 30d related to any wound complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Return to Operating Room (ROR)</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Reoperation for wound complication within 30 days involving incision and drainage in the operating room; opening the skin to drain a superficial soft tissue infection at bedside or in the office is not considered reoperation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day hospital readmissions</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Rehospitalization for wound complication within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rates of wound complications</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Individual rates of the incidence of each of the following:
Dehiscence (skin or fascia)
Seroma
Lymph leak
Infection (superficial or deep, using CDC Surgical Site Infection criteria)
Hematoma
Ischemia
Necrosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>30-day hospitalization costs</measure>
    <time_frame>admission to discharge; 30 days post procedure</time_frame>
    <description>Index hospitalization costs as well as all readmission days within 30d related to any wound complication</description>
  </other_outcome>
  <other_outcome>
    <measure>30-day hospital variable costs</measure>
    <time_frame>admission to discharge; 30 days post procedure</time_frame>
    <description>Variable costs (not charges) for each admission obtained from hospital administration</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Amputation</condition>
  <condition>Amputation; Postoperative, Sequelae</condition>
  <condition>Wound Dehiscence</condition>
  <condition>Seroma</condition>
  <condition>Wound Infection, Surgical</condition>
  <condition>Lymph Leakage</condition>
  <arm_group>
    <arm_group_label>Prevena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREVENA™ PEEL &amp; PLACE™ Dressing Kit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>sterile gauze dressing supplemented with an Ace wrap</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PREVENA™ PEEL &amp; PLACE™ Dressing Kit</intervention_name>
    <description>In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).</description>
    <arm_group_label>Prevena</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults 18 years or older

          2. Patients undergoing above-knee amputation (includes the revision of emergency
             guillotine amputations)

          3. Patients undergoing below-knee amputation (includes the revision of emergency
             guillotine amputations)

          4. Informed Consent signed by patient

        Exclusion Criteria:

          1. Minors under 18 years

          2. Women who are pregnant or breastfeeding

          3. Patients undergoing emergent or guillotine amputation

          4. Patients having BOTH legs amputated

          5. Patients with sensitivity to silver

          6. Unwilling or unable to provide informed consent

          7. Inability to comply with planned study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul DiMuzio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Anatale-Tardiff</last_name>
    <phone>2155034280</phone>
    <email>laura.anatale.tardiff@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Upstate University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Costanza, MD</last_name>
      <email>costanzm@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Costanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geena George</last_name>
      <email>geena.george@wmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeontaik Kwon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Alfaro, CRNP</last_name>
      <phone>215-887-5934</phone>
      <email>kalfaro@abingtonhealth.org</email>
    </contact>
    <investigator>
      <last_name>Danielle Pineda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Jubelirer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Parsons, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Sullivan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University/Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Anatale-Tardiff</last_name>
      <phone>215-503-4280</phone>
      <email>laura.anatale.tardiff@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Paul DiMuzio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawn Salvatore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Babak Abai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemelli Hospital</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>8, 00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Falsetti</last_name>
      <email>alessandra.falsetti@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Raffaele Landolfi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Marino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf</url>
    <description>National Healthcare Safety Network definition of Surgical Site Infection (SSI) Event</description>
  </link>
  <reference>
    <citation>Hasanadka R, McLafferty RB, Moore CJ, Hood DB, Ramsey DE, Hodgson KJ. Predictors of wound complications following major amputation for critical limb ischemia. J Vasc Surg. 2011 Nov;54(5):1374-82. doi: 10.1016/j.jvs.2011.04.048. Epub 2011 Aug 15.</citation>
    <PMID>21840153</PMID>
  </reference>
  <reference>
    <citation>Belmont PJ Jr, Davey S, Orr JD, Ochoa LM, Bader JO, Schoenfeld AJ. Risk factors for 30-day postoperative complications and mortality after below-knee amputation: a study of 2,911 patients from the national surgical quality improvement program. J Am Coll Surg. 2011 Sep;213(3):370-8. doi: 10.1016/j.jamcollsurg.2011.05.019. Epub 2011 Jul 1.</citation>
    <PMID>21723151</PMID>
  </reference>
  <reference>
    <citation>Stannard JP, Volgas DA, McGwin G 3rd, Stewart RL, Obremskey W, Moore T, Anglen JO. Incisional negative pressure wound therapy after high-risk lower extremity fractures. J Orthop Trauma. 2012 Jan;26(1):37-42. doi: 10.1097/BOT.0b013e318216b1e5.</citation>
    <PMID>21804414</PMID>
  </reference>
  <reference>
    <citation>Pachowsky M, Gusinde J, Klein A, Lehrl S, Schulz-Drost S, Schlechtweg P, Pauser J, Gelse K, Brem MH. Negative pressure wound therapy to prevent seromas and treat surgical incisions after total hip arthroplasty. Int Orthop. 2012 Apr;36(4):719-22. doi: 10.1007/s00264-011-1321-8. Epub 2011 Jul 15.</citation>
    <PMID>21761149</PMID>
  </reference>
  <reference>
    <citation>Grauhan O, Navasardyan A, Hofmann M, Müller P, Stein J, Hetzer R. Prevention of poststernotomy wound infections in obese patients by negative pressure wound therapy. J Thorac Cardiovasc Surg. 2013 May;145(5):1387-92. doi: 10.1016/j.jtcvs.2012.09.040. Epub 2012 Oct 27.</citation>
    <PMID>23111014</PMID>
  </reference>
  <reference>
    <citation>Hyldig N, Birke-Sorensen H, Kruse M, Vinter C, Joergensen JS, Sorensen JA, Mogensen O, Lamont RF, Bille C. Meta-analysis of negative-pressure wound therapy for closed surgical incisions. Br J Surg. 2016 Apr;103(5):477-86. doi: 10.1002/bjs.10084. Review.</citation>
    <PMID>26994715</PMID>
  </reference>
  <reference>
    <citation>Kwon J, Staley C, McCullough M, Goss S, Arosemena M, Abai B, Salvatore D, Reiter D, DiMuzio P. A randomized clinical trial evaluating negative pressure therapy to decrease vascular groin incision complications. J Vasc Surg. 2018 Dec;68(6):1744-1752. doi: 10.1016/j.jvs.2018.05.224. Epub 2018 Aug 17.</citation>
    <PMID>30126781</PMID>
  </reference>
  <reference>
    <citation>O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56.</citation>
    <PMID>497341</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03773575/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

